Welcome Remarks  -

• Alan F. Eisenberg, Executive Vice President, Emerging Companies and Business Development, Biotechnology Industry Organization (BIO)
• David Flores, Co-Founder, President & CEO, BioCentury Publications, Inc.

Plenary Session:  Lessons Learned from Various Transactions Between Japanese and U.S. Firms

This session will look at some of the most important transactions that took place over the past few years and will address the changes that have taken place in the Japan-U.S. dealmaking environment. 

Moderator:  George Montgomery, Managing Director, Montgomery & Co., LLC

Panelists:

• Masaki Doi, Ph.D., Vice President, Head of Business Development, Astellas Pharma Inc.
• Christopher Lynch, Executive Director, Corporate Licensing, Merck & Co., Inc.
• Arlene Morris, President & CEO, Affymax, Inc.
• Hiroaki Ogata, General Manager, Global Licensing & Business Development, Takeda Pharmaceutical Company Ltd.
• Carol Olson, Executive Vice President, Portola Pharmaceuticals, Inc.

Sponsored by:  Montgomery & Co., LLC

Partnering Meetings

Luncheon

Introducer - Tadao Suzuki, Ph.D., Senior Managing Director, Head of R&D, Daiichi Sankyo Co., Ltd.

Keynote Speaker - Koichiro Aramaki, Ph.D., Chairman & Chief Executive Officer, Kirin Brewery Co., Ltd.

Focus Session:  Japanese Spin Out/Specialty Pharma Model - What VCs Want to Fund

Specialty Pharma has received a lot of attention in the U.S. over the last few years, but it's a relatively new model in Japan.  Many Japanese mid-tier companies are looking at this model as a mechanism to improve earnings via a reduction of R&D costs on their P&L.

Moderator:  Simba Gill, Ph.D., CEO, moksha8 and Venture Partner, Entrepreneur in Residence, TPG Growth

Panelists: 

• Geoffrey Duyk, M.D., Ph.D., Managing Director, TPG Growth
• Wendy Johnson, Venture Partner, ProQuest Investments
• Goro Takeda, Kauffman Fellow, Itochu Corporation
• Kazuhiko Takeshige, Ph.D., Senior Manager, Business Alliances Group, Kyowa Hakko Kogyo Co., Ltd.
• Jeffrey Wager, M.D., President & CEO, Artisan Pharma, Inc.

Sponsored by:  TPG Growth and moksha8

Focus Session:  The Asian Biopharma Challenge - Moving up the Value Chain

Much of the recent focus on Asian companies in the biopharma industry has been on biogenerics, outsourced clinical development and contract manufacturing services.  The long-term sustainability of these enterprises hinges on their ability to transition to a product-based model, and ultimately to access proprietary product programs.  This session will explore the trend of Asian companies leading this transition, as well as the implications going forward. 

Moderator:  Vivian Lee, Managing Director, Aqua Partners LLC

Panelists:

• James Foley, Ph.D., President & CEO, SMART Biosciences, Inc.
• Gerhard Klement, President & CEO, Reliance Biopharmaceuticals
• Saul Mashaal, PhMb, Chairman & CEO, SciGen Group and Chairman, SciTech Group
• Corinne Savill, Global Head, Search & Evaluation, Business Development and Licensing, Novartis Pharma AG
• Zhi Yang, Ph.D., Managing Partner, BioVeda Capital

7:00 - 9:00 p.m.

Gala Reception - Roppongi Hills Club (Mori Tower)

Welcoming Remarks by:

• James C. Mullen, President & CEO, Biogen Idec, Inc.
• Tsutomu Tanaka, Senior Managing Director, Mitsubishi UFJ Securities Co., Ltd.

Sponsored by: 

• Mitsubishi UFJ Securities Co., Ltd.
• Montgomery & Co., LLC

Plenary Session:  Building Locally and Expanding Globally

Senior biotech and pharma executives from the Asia-Pacific region will discuss how they are building their companies to address therapeutic needs inside their home markets, while addressing the challenges of being able to compete as fully integrated companies throughout Asia and beyond into U.S. and Europe.

Moderator:  David Flores, Co-Founder, President & CEO, BioCentury Publications, Inc.

Panelists: 

• Mel Bridges, BSc, Non-Executive Chairman, Peptech Ltd.
• Tony Buss, Ph.D., President & CEO, MerLion Pharmaceuticals Pte Ltd.
• Ming-Chu Hsu, Ph.D., President & CEO, TaiGen Biotechnology Co., Ltd.
• Michael Hui, CEO, Shanghai ChemPartner Co., Ltd.
• Patrick Peter Keohane, Ph.D., Vice President, Head of Japan R&D, AstraZeneca K.K.
• In-Chull Kim, Ph.D., CEO, LG Life Sciences, Ltd.

Sponsored by:  BioCentury Publications, Inc.

Luncheon

Keynote Speaker - Anthony Rosenberg, BSc, MSc, Global Head of Business Development & Licensing, Novartis Pharma AG

Sponsored by:  Novartis International AG

Focus Session:  Delivering on the Promise of Cellular Therapies - Engineered Cells May Provide the Solution

Whether it's immuno-therapies, regenerative medicine, or cell replacement therapy, using unmodified cells has not been effective at treating significant diseases.  Recent advances in cell biology make it possible for cells to be safely and efficiently engineered to produce more effective therapies.  This session will evaluate cellular engineering as a potential route to the development of cellular therapies and outline the remaining challenges ahead as we strive to realize the therapeutics promise of cell therapies.

Moderator:  Malcolm Brenner, M.B., Ph.D., Professor of Medicine and of Pediatrics and Director of the Center for Cell and Gene Therapy, Baylor College of Medicine

Panelists:

• Sinclair Dunlop, Managing Partner, MASA Life Science Ventures, LP
• Jane Lebkowski, Ph.D., Vice President, R&D Regenerative Medicine, Geron Corporation
• Duncan Stewart, M.D., Head, Division of Cardiology, University of Toronto (Charm)

Sponsored by:  MaxCyte, Inc. and MDBio